AMENDMENTS

In the Claims

Please amend the claims as follows.



- 1. (currently amended) A method for transferring genetic material into a mammalian muscle cell or tumor cell, comprising administering to the muscle cell or tumor cell a recombinant genetic material comprising: The use of a non-human adenoviral vector for producing a means for the transfer of genetic material by local injection into muscle cells or muscle cell complexes of mammals which display altered, also pathological manifestations, or into tumors, for the therapy of congenital, acquired or malignant disorders, comprising the coat of a non-human adenovirus and genetic material which is packaged therein and which comprises
- (a) DNA sequences of a non-human adenovirus which code for at least a viral protein coat, and
- (b) one or more DNA sequences which code for peptides or polypeptides which are heterologous in relation to the non-human adenovirus, in operative linkage to expression control sequences.
- 2. (currently amended) The <u>method of claim 1, wherein the adenovirus is</u> use as claimed in claim 1, characterized in that the virus is an adenovirus from a non-human species selected from mammals and birds.
- 3. (currently amended) The <u>method of claim 2, wherein the adenovirus is</u> use as claimed in claim 2, characterized in that the virus is an ovine or bovine adenovirus.
- 4. (currently amended) The <u>method of claim 2, wherein the adenovirus is use as claimed in claim 2, characterized in that the virus is</u> an ovine or bovine mastadenovirus or atadenovirus.

- 5. (currently amended) The method of claim 1, wherein the adenovirus use as claimed in claim 3 and 4, characterized in that the ovine virus is the OAV isolate 287.
- 6. (currently amended) The <u>method of any of claims 1 to 5</u>, wherein the cell is a human cell. use as claimed in any of claims 1 to 5 for transferring genetic material into human cells.
- 7. (currently amended) The <u>method of any of claims 1 to 5, wherein the cell is a human skeletal muscle cell.</u> use as claimed in any of claims 1 to 6 for transferring genetic material into skeletal muscle.
- 8. (currently amended) The method of claim 7 wherein the human muscle cell is use as elaimed in any of claims 1 to 7, characterized in that the muscle cells are selected from myocytes/myotubes/myofibers, fibroblasts, dendritic cells, endothelial cells and combinations thereof.
- 9. (currently amended) The method of any of claims 1 to 5 or 8 wherein the administration step is repeated at least once. use as claimed in any of claims 1 to 8 4, characterized in that the vector is administered more than once.
- 10. (currently amended) A method for transferring genetic material into a cell for the production of recombinant protein in cell culture, comprising administering to the cell a recombinant genetic material comprising. The use of a non-human adenoviral vector for producing a means for the transfer of genetic material for the production and isolation of recombinant proteins in cell culture, comprising the coat of a non-human adenovirus and genetic material which is packaged therein and which comprises
- (a) DNA sequences of a non-human adenovirus which code for at least a viral protein coat and
- (b) one or more DNA sequences which code for peptides or poly peptides which are heterologous in relation to the non-human adenovirus, in operative linkage to expression control sequences.

Response to Office Action 10/049,301 Page 2

- 11. (New) The method of claim 10, wherein the adenovirus is a non-human species selected from mammals and birds.
- 12. (New) The method of claim 11, wherein the adenovirus is an ovine or bovine adenovirus.
- 13. (new) The method of claim 11, wherein the adenovirus is an ovine or bovine mastadenovirus or atadenovirus.
 - 14. (New) The method of claim 10, wherein the adenovirus is the OAV isolate 287.
 - 15. (New) The method of any of claims 10 to 14, wherein the cell is a human cell.
- 16. (New) The method of any of claims 10 to 14, wherein the cell is a human skeletal muscle cell.
- 17. (New) The method of claim 16, wherein the human muscle cell is selected from myocytes/myotubes/myofibers, fibroblasts, dendritic cells, endothelial cells and combinations thereof.